Date prepared: 04\/05\/2022<\/p>\n\n\n\n
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information <\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that on April 5, 2022 the Management Board of the Warsaw Stock Exchange (\u201cWSE\u201d) adopted a resolution in which it stated that pursuant to \u00a7 19.1 and \u00a7 19.2 of the WSE Rules, 30,000 ordinary C-series bearer shares of Celon Pharma S.A., having the nominal value of PLN 0.10 each, designated with the \u201cPLCLNPH00080\u201d code by the Central Securities Depository of Poland, have been admitted to stock exchange trading in the primary market. At the same time, the GPW Management Board decided to introduce the aforementioned shares to trading on the primary market as of April 11, 2022, subject to the assimilation of these shares with the shares in the exchange trade, designated with the \u201cPLCLNPH00015\u201d code, by the Central Securities Depository of Poland on April 11, 2022.<\/p>\n\n\n\n
On April 5, 2022 the Central Securities Depository of Poland issued a statement informing that it has decided to assimilate 30,000 ordinary bearer shares of Celon Pharma S.A. on April 11, 2022, designated with the \u201cPLCLNPH00080\u201d code with the Company\u2019s share which are in the exchange trade, designated with the \u201cPLCLNPH00015\u201d code. In light of the above, the condition specified in the above-mentioned resolution of the GPW Management Board shall be met on April 11, 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"